TY - JOUR
T1 - The course of mycosis fungoides under cytokine pathway blockers
T2 - A multicentre analysis of real-life clinical data
AU - Amitay-Laish, Iris
AU - Guenova, Emmanuella
AU - Ortiz-Romero, Pablo L.
AU - Vico-Alonso, Cristina
AU - Rozati, Sima
AU - Geskin, Larisa J.
AU - Nikolaou, Vasiliki
AU - Papadavid, Evangelia
AU - Barzilai, Aviv
AU - Pavlovsky, Lev
AU - Didkovsky, Elena
AU - Prag Naveh, Hadas
AU - Akilov, Oleg E.
AU - Hodak, Emmilia
N1 - Publisher Copyright:
© 2020, Medical Journals/Acta D-V. All rights reserved.
PY - 2020/9
Y1 - 2020/9
N2 - Literature regarding the effect of biologics on the course of mycosis fungoides (MF) is scarce. This multicentre study analysed retrospective data on 19 patients with MF, who were treated with biologics; 12 for inflammatory conditions coexisting with MF, and 7 for MF misdiagnosed as an inflammatory skin disease. Eight patients were treated with anti-tumour necrosis factor-α-monotherapy; 6 had early-stage MF, in 3 patients MF preceded and in 3 MF was diagnosed after initiation of biologics, with no stage-progression or with stable disease, respectively (median treatment time concurrent with MF 57 months). Two patients had advanced stage MF: IIB, treated for 15 months with no stage-progression, and IVA1, treated for 8 months, died of disease 10 months later. The other 11/19 patients received anti-interleukin-17A and/or anti-interleukin-12/23 or anti-interleukin-23 (with/without anti-tumour necrosis factor-α/anti-interleukin-4/13), with stage-progression in 8 patients after a median of 8 months’ treatment. Although, in general, biologics should be avoided in patients with MF, these results indicate that anti-tumour necrosis factor-α-monotherapy might not aggravate the disease course in early-stage patients. Interleukin-17A, interleukin-12/23 and interleukin-23 pathway-blockers may prompt progression of MF.
AB - Literature regarding the effect of biologics on the course of mycosis fungoides (MF) is scarce. This multicentre study analysed retrospective data on 19 patients with MF, who were treated with biologics; 12 for inflammatory conditions coexisting with MF, and 7 for MF misdiagnosed as an inflammatory skin disease. Eight patients were treated with anti-tumour necrosis factor-α-monotherapy; 6 had early-stage MF, in 3 patients MF preceded and in 3 MF was diagnosed after initiation of biologics, with no stage-progression or with stable disease, respectively (median treatment time concurrent with MF 57 months). Two patients had advanced stage MF: IIB, treated for 15 months with no stage-progression, and IVA1, treated for 8 months, died of disease 10 months later. The other 11/19 patients received anti-interleukin-17A and/or anti-interleukin-12/23 or anti-interleukin-23 (with/without anti-tumour necrosis factor-α/anti-interleukin-4/13), with stage-progression in 8 patients after a median of 8 months’ treatment. Although, in general, biologics should be avoided in patients with MF, these results indicate that anti-tumour necrosis factor-α-monotherapy might not aggravate the disease course in early-stage patients. Interleukin-17A, interleukin-12/23 and interleukin-23 pathway-blockers may prompt progression of MF.
KW - Anti-IL-12/23
KW - Anti-IL17A
KW - Anti-IL23
KW - Anti-TNFα
KW - Biologic treatment
KW - Cutaneous T cell lymphoma
KW - Mycosis fungoides
UR - http://www.scopus.com/inward/record.url?scp=85092432952&partnerID=8YFLogxK
U2 - 10.2340/00015555-3642
DO - 10.2340/00015555-3642
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 32965506
AN - SCOPUS:85092432952
SN - 0001-5555
VL - 100
SP - 1
EP - 7
JO - Acta Dermato-Venereologica
JF - Acta Dermato-Venereologica
IS - 16
ER -